RESEARCH

Multi-responsive nanofibers composite gel for local drug delivery to inhibit recurrence of glioma after operation

Yufu Zhu^{1,2†}, Jun Jia^{1†}, Gang Zhao^{1†}, Xuyang Huang¹, Lansheng Wang¹, Yongkang Zhang¹, Long Zhang¹, Naveena Konduru⁴, Jun Xie⁵, Rutong Yu^{1,2*} and Hongmei Liu^{1,2,3*}

Abstract

Background: The postoperative recurrence of malignant gliomas has presented a clinical conundrum currently. Worse, there is no standard treatment for these recurrent tumours. Therefore, novel promising methods of clinical treatment are urgently needed.

Methods: In this study, we synthesized reactive oxygen species (ROS)-triggered poly(propylene sulfide)60 (PPS60) mixed with matrix metalloproteinases (MMPs)-responsive triglycerol monostearate (T) lipids and TMZ. The mixed solution could self-assemble at 50 $^{\circ}$ C to generate hydrogels with MMPs- and ROS-responsiveness. We explored whether the T/PPS + TMZ hydrogel could achieve the MMP- and ROS-responsive delivery of TMZ and exert anti-glioma regrowth effects in vitro and in vivo. These results demonstrated that the T/PPS + TMZ hydrogel significantly improved the curative effect of TMZ to inhibit postsurgical recurrent glioma.

Results: The results confirmed the responsive release of TMZ encapsulated in the T/PPS + TMZ hydrogel, and the hydrogel showed excellent performance against glioma in an incomplete glioma operation model, which indicated that the T/PPS + TMZ hydrogel effectively inhibited the growth of recurrent glioma.

Conclusion: In summary, we successfully developed injectable MMPs- and ROS-responsive hydrogels that could achieve the sustained release of TMZ in the surgical cavity to inhibit local recurrent glioma after surgery.

Keywords: Local drug delivery, Glioma, Hydrogel, Operation, Recurrence

Background

Glioma is the most common type of primary tumour in the brain and is derived from the nerve epithelium [1, 2]. Although therapies against malignant gliomas, including surgery, radiotherapy and chemotherapy, have been widely used, the therapeutic effect remains poor [3–6]. The median survival of malignant glioma patients is less than 14.6 months [7, 8]. The hardest problem in treating

¹Yufu Zhu, Jun Jia, and Gang Zhao contributed equally to this work ¹Institute of Nervous System Diseases, Xuzhou Medical University,

© The Author(s) 2021. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/

 $\frac{1}{2}$ zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

research and practice.





glioma is postoperative recurrence. Complete resection is deemed impossible in high-grade gliomas, and residual

glioma cells contribute to postoperative glioma recur-

rence [9]. Clinical studies found that 80–90% of recurrent gliomas occur within 2 cm of the original region [8,

10, 11]. Decreasing glioma recurrence caused by residual

tumour cells has become an important topic in clinical

Currently, there are no specific cures for recurrent gliomas. TMZ is still a first-line chemotherapeutic for the

clinical treatment of recurrent gliomas [12-14]. How-

ever, the therapeutic efficacy of TMZ is often limited by

several factors, including its short half-life in vivo, rapid

Open Access

^{*}Correspondence: yu.rutong@163.com; liuhongmei816@sina.com

Xuzhou 221002, China

Full list of author information is available at the end of the article